AI Article Synopsis
Article Abstract
Background: The importance of the genetic background of melanoma cells to the individual susceptibility to treatment has become apparent. In Caucasians, BRAF mutations are frequently detected in lesions on the skin of younger patients compared to NRAS and KIT mutations. However, clinical and pathological characteristics associated with BRAF, NRAS and KIT mutations have not been fully evaluated in East Asians.
Objective: To clarify clinical and pathological characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
Methods: Clinical data were retrospectively collected from 11 hospitals in Japan. BRAF, NRAS and KIT mutations were evaluated with polymerase chain reaction and Sanger sequencing. The relationships between these gene mutations and pathological and clinical findings were analyzed.
Results: The number of cases examined was 171 (primary: 135, metastases: 11, paired: 25), and all were Japanese patients. The detection rates of BRAF, NRAS and KIT mutations were 30.4%, 12.3% and 12.9%, respectively. Compared with the wild type, the presence of BRAF mutations was significantly associated with younger age (median, 50.0 years vs. 70.0 years, p<0.001). BRAF mutation was frequently detected in the lesions of the scalp (80%; 4/5), trunk (72.0%; 18/25), extremities (56.7%; 17/30) and neck (44.4%; 4/9), and the least prevalent were the face (22.2%; 2/9), nail (12.5%; 3/24), palm or sole (8.9%; 4/45) and mucosa (0%). NRAS mutations were prevalent in the face (33.3%) and palm or sole (20.0%), and the median age of these patients was 70.5 years. A KIT mutation was observed in the nail apparatus (25%), palm or sole (15.6%) and mucosa (18.2%). The median age of the patients with a KIT mutation was 63.0 years. Heterogeneity of mutations between primary and metastatic lesions was detected in six of 25 cases (24%). Solar elastosis was identified in 12 of 71 cases (15.3%), among which four cases harbored BRAF(V600E) (2 cases), BRAF(V600K), NRAS(Q61K) or NRAS(Q61L), respectively.
Conclusion: Some clinical characteristics associated with BRAF, NRAS and KIT mutations were observed in Japanese patients, and we observed both similarities to and differences from those of Caucasians. Our findings could provide useful information in efforts to clarify the tumor genesis of malignant melanomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jdermsci.2015.07.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02.
Int J Hematol
December 2024
Department of Hematology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
HM-SCREEN-Japan is a multicenter collaborative project in Japan to evaluate the clinical utility of a cancer genome panel in the treatment of acute myeloid leukemia (AML). The HM-SCREEN-JAPAN02 study used the Amoy Myeloid Panel with the HANDLE system, which enables efficient and rapid sequencing, as the genomic testing kit. The Amoy Myeloid Panel targets 53 genes with established clinical significance or high prevalence.
View Article and Find Full Text PDFGenomic differences of patients with hematologic malignancies in different age groups.
Commun Biol
December 2024
Department of Hematology, Peking University First Hospital, Beijing, China.
Article Synopsis
- Hematologic malignancies significantly impact the health of children, young adults, and older adults, yet their biological causes are not well understood.
- A study revealed notable differences in clinical features and genomic mutations between children/young adults (CYAs) and older adults (OAs) in these diseases, including lower mutational burdens in CYAs for many key genes.
- The research identified specific genes with varying mutation rates and emphasized the need for age-oriented personalized treatment options based on the distinct genetic and clinical landscapes of CYAs and OAs.
The prognostic value of tumor-infiltrating lymphocytes in vulvovaginal melanoma.
Int J Gynecol Cancer
December 2024
Department of Surgical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Article Synopsis
- The study aimed to investigate the relationship between the immune microenvironment and survival outcomes in patients with vulvovaginal melanoma.
- It involved a retrospective analysis of 42 patients, examining tumor-infiltrating lymphocytes and genetic mutations, with significant findings on immune cell presence related to better disease-free survival.
- The researchers concluded that specific types of tumor-infiltrating lymphocytes could indicate disease progression and response to treatments, suggesting the need for further multicenter studies to confirm these results.
Genetic Characteristics of Cutaneous, Acral, and Mucosal Melanoma in Japan.
Cancer Med
November 2024
Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Article Synopsis
- - Acral and mucosal melanomas are more common in Asians compared to Caucasians, while cutaneous melanomas are mainly found in Caucasians; this study focuses on the genetic traits of melanomas in Japanese patients due to under-research in this area.
- - Analysis of 104 Japanese melanoma samples revealed that 94% had driver mutations, with significant mutations differing among melanoma types: BRAF was notable in cutaneous, while acral exhibited mutations in KIT and others, and mucosal showed various driver mutations like NRAS and KRAS.
- - The findings suggest a lower tumor mutational burden in East Asian cutaneous melanoma, potentially impacting the effectiveness of immune checkpoint inhibitors and emphasizing the necessity for personalized treatment strategies based on
Prognostic significance of actionable next-generation sequencing multigene panel in esophageal cancer treatment.
Eur Rev Med Pharmacol Sci
November 2024
Department of Gastroenterological Surgery, University of Health Sciences, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.
Objective: Next-generation sequencing (NGS) has been offered as a large-scale and effective genomic analyzing tool. In this research, we seek to examine the possible benefits of an actionable mutation panel in association with clinical and pathological features in the treatment of esophageal cancer.
Patients And Methods: In our study, 85 cases whose diagnosis of carcinoma was confirmed histopathologically either by endoscopic biopsy or esophageal surgery between 2010 and 2020 were identified from the hospital database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!